Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in ...

Nanoneedle technology offers the capability to simultaneously quantify titers of true, full viral genomes and a range of ...

Yet, large-scale AAV production is still a bottleneck for commercialization. A new, streamlined AAV purification process that is both universal and scalable eases that constraint. After the AAV ...

This intrinsic property of AAV to undergo intermolecular concatamerization ... expression of more than 600-fold from a minimal simian virus 40 (SV40) promoter and an increase in expression of ...

Adeno-associated virus 2 (AAV)-based vectors have gained attention as a potentially useful alternative to the more commonly used retroviral and adenoviral vectors for human gene therapy.

The company will discontinue development of its original ALS gene therapy candidate VY9323 amid toxic effects in nonhuman ...

Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of ...

and/or chemically modified AAV particles along with improvements in the technology for their clinical-grade manufacturing including production, purification, quality control and batch release. Still, ...

The nano-complex is constructed by the sequential mixing of AAV9, TA, and polymers in an aqueous solution. The nano-complexes released the loaded-AAV intracellularly and exhibited efficient gene ...